Skip to main content
USA News
 

MASON, Ohio --(BUSINESS WIRE)--Nov. 8, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30 th Annual Healthcare Conference in New

 

Worldwide revenue of $49 .9 million – an increase of 18.5% year over year U.S. revenue of $39 .8 million – an increase of 19.1% year over year International revenue of $10 .2 million – an increase of 16.2% year over year MASON, Ohio --(BUSINESS WIRE)--Nov. 1, 2018-- AtriCure, Inc.

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 22, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will be participating in upcoming investor conferences.

 

MASON, Ohio --(BUSINESS WIRE)--Oct. 11, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018 .

 

MASON, Ohio --(BUSINESS WIRE)--Jul. 16, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Canaccord Genuity 38 th Annual Growth Conference at the

 

Landmark study is the first prospective, randomized study comparing the Convergent approach to endocardial catheter ablation in persistent and long-standing persistent atrial fibrillation patients MASON, Ohio --(BUSINESS WIRE)--Aug. 28, 2018-- AtriCure, Inc.

 

MASON, Ohio --(BUSINESS WIRE)--Aug. 21, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Morgan Stanley Global Healthcare Conference at the Grand Hyatt

 

Updates 2018 Financial Outlook Worldwide revenue of $51.8 million – an increase of 14.5% year over year U.S. revenue of $40.8 million – an increase of 14.9% year over year International revenue of $11.0 million – an increase of 13.1% year over year Positive adjusted EBITDA of $0.8 million MASON,

 

<p>MASON, Ohio--(BUSINESS WIRE)--Jul. 11, 2018-- AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will release its second quarter 2018 financial results on Wednesday, August 1, 2018. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Wednesday, August 1, 2018 to discuss its second quarter 2018 financial ...</p>

 

MASON, Ohio --(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018 , in New York City from 8:30

 

MASON, Ohio --(BUSINESS WIRE)--Jun. 12, 2018-- AtriCure, Inc. ( Nasdaq: ATRC ), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, will host an analyst and institutional investor meeting on Tuesday, June 26, 2018 , in New York City from 8:30